TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Hernández, José M.
AU  - Hernández, Miguel T.
AU  - Gutiérrez Gutiérrez, Norma Carmen
AU  - Palomera, Luis
AU  - Fuertes, M.
AU  - Díaz-Mediavilla, Joaquín
AU  - Lahuerta, Juan José
AU  - De la Rubia, Javier
AU  - Terol, María-José
AU  - Sureda, Anna
AU  - Bargay, Joan
AU  - Ribas, Paz
AU  - De Arriba, Felipe
AU  - Alegre, Adrian
AU  - Oriol, Albert
AU  - Carrera, Dolores
AU  - García-Laraña, José
AU  - García Sanz, Ramón
AU  - Bladé, Joan
AU  - Prósper, Felipe
AU  - Mateo, Gemma
AU  - Esseltine, Dixie-Lee
AU  - van de Velde, Helgi
AU  - San Miguel Izquierdo, Jesús Fernando
PY  - 2006
UR  - http://hdl.handle.net/10366/154234
AB  - [EN]Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). However, complete responses (CRs) are rare. Bortezomib is active in patients with relapsed MM,...
LA  - eng
PB  - American Society of Hematology
KW  - Mieloma múltiple
KW  - Disease-Free Survival
KW  - Immunophenotyping
KW  - Aged
KW  - Boronic Acids
KW  - Humans
KW  - Pyrazines
KW  - Melphalan
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Antineoplastic Agents
KW  - Multiple Myeloma
KW  - Maximum Tolerated Dose
KW  - Cohort Studies
KW  - Prednisone
TI  - Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
DO  - 10.1182/blood-2006-04-019778
T2  - Blood
VL  - 108
M2  - 2165
ER  -